Logo

Cincinnati Children’s Hospital Medical Center (CCHMC)

Cincinnati, Ohio

 

About the Center

Cincinnati Children’s Hospital Medical Center (CCHMC) is the coordinating center for the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Our specialists within the Cincinnati Center for Eosinophilic Disorders (CCED) understand the ups and downs of living with eosinophilic disorders, which are often misdiagnosed and misunderstood.

For families dealing with eosinophilic disorders, the road to diagnosis can be frustrating and challenging since symptoms masquerade as a number of conditions. However, once diagnosed, symptoms of these disorders can be effectively managed in many cases.

We are international leaders in caring for patients with eosinophilic conditions and researching the cure. Our multidisciplinary team has extensive experience with these rare disorders. We have intense interest in eosinophilic disorders, their effects on health and their impact on individuals and families.

The CCED was the first center established in the United States to bring together experts in various disciplines to evaluate, treat and study these chronic medical problems in children and adults. Our multidisciplinary structure, composed of professionals in various divisions throughout Cincinnati Children’s, is founded in collaboration. These collaborations allow us to draw upon the expertise of specialists while permitting a unified plan of care tailored to the needs of the patient and family.

Our center conducts leading research (basic, translational and clinical) on eosinophilic gastrointestinal diseases, as well as leading clinical care, and education concerning these diseases.

Cincinnati Children’s Hospital Medical Center (CCHMC) main website
Allergy and Immunology Division at CCHMC

Related research studies at this Center:

  1. A Study of Antolimab (AK002) in Patients With Active Eosinophilic Esophagitis (Allakos)
  2. A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Allakos)
  3. Efficacy and safety of benralizumab in patients with EoE (Astrazeneca) (No NCT yet)
  4. OMEGA Study: https://clinicaltrials.gov/ct2/show/NCT02523118?term=NCT02523118&draw=1&rank=1
  5. DEGAS Study: https://clinicaltrials.gov/ct2/show/NCT03678545?term=NCT03678545&draw=2&rank=1

 

Center Personnel


 

CCHMC Contact Information